EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis

Richard J Nowak, Michael Benatar iD, Emma Ciafaloni, James F Howard, M Isabel Leite, Kimiaki Utsugisawa, John Vissing iD, Mikhail Rojavin, Qing Li, Fengming Tang, Yanping Wu, Nishi Rampal und 2 weitere

New England Journal of Medicine · 19.06.2025 · 392 (23) · 2309-2320

DOI: 10.1056/nejmoa2501561 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.06.2025. Verfasst von Richard J Nowak und 13 weiteren Autor:innen. Beteiligte Einrichtung: Yale University, New Haven, CT. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Myasthenia Gravis. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Amgen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMyasthenia GravisAdultFemaleHumansMaleMiddle AgedActivities of Daily LivingAutoantibodiesDouble-Blind MethodGlucocorticoidsReceptor Protein-Tyrosine KinasesReceptors, CholinergicTreatment OutcomeSeverity of Illness Index

Substanzen

Antibodies, Monoclonal, HumanizedAutoantibodiesGlucocorticoidsMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, Cholinergicinebilizumab

Autor:innen und Institutionen

  • Yale University, New Haven, CT.
  • University of Miami Miller School of Medicine, Miami.
  • University of Rochester, Rochester, NY.
  • University of North Carolina, Chapel Hill.
  • University of Oxford, Oxford, United Kingdom.
  • Hanamaki General Hospital, Hanamaki, Japan.

ORCID-Profile: Michael Benatar, John Vissing

Förderung

  • Amgen Inc.

Zitieren

APA

Nowak, R. J., Benatar, M., Ciafaloni, E., Howard, J. F., Leite, M. I., Utsugisawa, K., Vissing, J., Rojavin, M., Li, Q., Tang, F., Wu, Y., Rampal, N., Cheng, S., & MINT Investigators (2025). A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. New England Journal of Medicine, 392(23), 2309-2320. https://doi.org/10.1056/nejmoa2501561

Vancouver

Nowak RJ, Benatar M, Ciafaloni E, Howard JF, Leite MI, Utsugisawa K, et al. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. New England Journal of Medicine. 2025;392(23):2309-2320. doi:10.1056/nejmoa2501561

BibTeX
@article{Nowak2025,
  author = {Nowak, Richard J and Benatar, Michael and Ciafaloni, Emma and Howard, James F and Leite, M Isabel and Utsugisawa, Kimiaki and Vissing, John and Rojavin, Mikhail and Li, Qing and Tang, Fengming and Wu, Yanping and Rampal, Nishi and Cheng, Sue and MINT Investigators, MINT Investigators},
  title = {A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {23},
  pages = {2309--2320},
  doi = {10.1056/nejmoa2501561}
}
Kostenlos starten →